EPI-USE Labs Limited is a limited company established in November 2014, operating under Reg: 09302382 and currently active. The company specializes in providing consultancy services focused primarily on the diagnosis, management, and treatment of exocrine pancreatic insufficiency (EPI). This condition results from an inadequate production or secretion of digestive enzymes by the pancreas, a complex process affecting the digestive system. Our core expertise lies specifically within the areas of pancreatitis and cystic fibrosis patients. We cater to individuals diagnosed with these conditions through tailored assessment methodologies and strategic support programs. We offer expert advice on enzyme replacement therapy (ERT), dietary modifications, and ongoing monitoring protocols designed to optimize patient outcomes. EPI-USE Labs Limited operates internationally, demonstrating a commitment to global healthcare solutions. While we currently have a limited workforce, our organizational structure supports a significant international presence through strategic partnerships and collaborations. Our size is estimated to be relatively modest, focusing primarily on delivering specialized consultancy services within the UK and Europe. Currently, we are categorized as a Skilled Worker under Visa regulations, with an A rating indicating a strong aptitude for our role. We leverage our expertise in this area to support patients facing challenges related to EPI.

EPI-USE Labs Limited is a limited company established in November 2014, operating under Reg: 09302382 and currently active. The company specializes in providing consultancy services focused primarily on the diagnosis, management, and treatment of exocrine pancreatic insufficiency (EPI). This condition results from an inadequate production or secretion of digestive enzymes by the pancreas, a complex process affecting the digestive system. Our core expertise lies specifically within the areas of pancreatitis and cystic fibrosis patients. We cater to individuals diagnosed with these conditions through tailored assessment methodologies and strategic support programs. We offer expert advice on enzyme replacement therapy (ERT), dietary modifications, and ongoing monitoring protocols designed to optimize patient outcomes. EPI-USE Labs Limited operates internationally, demonstrating a commitment to global healthcare solutions. While we currently have a limited workforce, our organizational structure supports a significant international presence through strategic partnerships and collaborations. Our size is estimated to be relatively modest, focusing primarily on delivering specialized consultancy services within the UK and Europe. Currently, we are categorized as a Skilled Worker under Visa regulations, with an A rating indicating a strong aptitude for our role. We leverage our expertise in this area to support patients facing challenges related to EPI.